Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab pharmacokinetics comparison in healthy volunteers
NCT05796479Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlitelimab (3 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration Observed, Area Under the Curve from Time of Dosing to Last Measurable Concentration and 1 more. Started Apr 2022; status: completed.
02
Drugs
amlitelimab
Beyond the preview
Go deeper on NCT05796479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796479.